16,742 Shares in Incyte Co. (NASDAQ:INCY) Bought by New Age Alpha Advisors LLC

New Age Alpha Advisors LLC bought a new stake in Incyte Co. (NASDAQ:INCY) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 16,742 shares of the biopharmaceutical company’s stock, valued at approximately $1,156,000.

A number of other institutional investors have also bought and sold shares of the company. Norges Bank bought a new stake in shares of Incyte during the 4th quarter valued at about $121,890,000. NEOS Investment Management LLC lifted its stake in Incyte by 35.0% in the fourth quarter. NEOS Investment Management LLC now owns 36,453 shares of the biopharmaceutical company’s stock valued at $2,518,000 after buying an additional 9,457 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Incyte by 13.5% during the 4th quarter. JPMorgan Chase & Co. now owns 323,640 shares of the biopharmaceutical company’s stock worth $22,354,000 after buying an additional 38,550 shares in the last quarter. Elo Mutual Pension Insurance Co grew its position in shares of Incyte by 34.8% during the 4th quarter. Elo Mutual Pension Insurance Co now owns 19,501 shares of the biopharmaceutical company’s stock worth $1,347,000 after buying an additional 5,039 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of Incyte by 5.5% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 248,875 shares of the biopharmaceutical company’s stock valued at $17,329,000 after acquiring an additional 13,026 shares in the last quarter. Institutional investors own 96.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on INCY shares. Stifel Nicolaus raised their price target on shares of Incyte from $75.00 to $77.00 and gave the stock a “hold” rating in a report on Monday, February 10th. Wells Fargo & Company raised their target price on Incyte from $68.00 to $70.00 and gave the company an “equal weight” rating in a research note on Thursday, December 19th. UBS Group initiated coverage on Incyte in a research note on Tuesday, December 17th. They set a “neutral” rating and a $77.00 price target on the stock. William Blair cut Incyte from an “outperform” rating to a “market perform” rating in a research note on Tuesday, March 18th. Finally, Citigroup lowered their target price on Incyte from $97.00 to $88.00 and set a “buy” rating on the stock in a research report on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $74.88.

Incyte Trading Down 0.1 %

NASDAQ:INCY opened at $60.55 on Tuesday. Incyte Co. has a 52 week low of $50.35 and a 52 week high of $83.95. The firm has a 50-day moving average price of $69.31 and a two-hundred day moving average price of $70.12. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.94 and a current ratio of 1.97. The firm has a market cap of $11.72 billion, a price-to-earnings ratio of 224.27, a price-to-earnings-growth ratio of 0.41 and a beta of 0.76.

Incyte (NASDAQ:INCY) last issued its quarterly earnings results on Monday, February 10th. The biopharmaceutical company reported $1.09 EPS for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.48). Incyte had a net margin of 0.77% and a return on equity of 0.05%. On average, equities analysts expect that Incyte Co. will post 4.86 earnings per share for the current fiscal year.

Insider Transactions at Incyte

In other news, EVP Sheila A. Denton sold 599 shares of the firm’s stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $69.99, for a total transaction of $41,924.01. Following the completion of the sale, the executive vice president now owns 25,848 shares in the company, valued at $1,809,101.52. This trade represents a 2.26 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Barry P. Flannelly sold 19,807 shares of Incyte stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $67.69, for a total transaction of $1,340,735.83. Following the completion of the sale, the executive vice president now directly owns 33,567 shares in the company, valued at $2,272,150.23. This trade represents a 37.11 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 46,827 shares of company stock worth $3,322,618 in the last ninety days. Company insiders own 17.60% of the company’s stock.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.